Categories: News

Jeffrey Modell Foundation Launches Global Speaker Series

Uniting the global PI community to accelerate early diagnosis, education, and collaboration — 
with CME credit through Columbia University.

NEW YORK, Oct. 22, 2025 /PRNewswire/ — The Jeffrey Modell Foundation (JMF) launched the JMF Speaker Series, a global education initiative designed to inspire connection, accelerate innovation, and transform how Primary Immunodeficiency (PI) is understood, diagnosed, and treated.

The JMF Speaker Series is the first educational event of its kind to bring physicians, researchers, nurses, patients, families, and advocates together in a shared virtual space. These engaging virtual events will highlight groundbreaking research and discovery, share cutting-edge developments, and create new opportunities for collaboration.

The inaugural event, “PI: Past. Present. Possible.” will take place on November 10, 2025. This one-hour Zoom webinar will include a live Q&A session hosted by Dr. Lisa Forbes Satter. Registration is free and open to participants worldwide. Sessions will be presented in clear, accessible language open to clinicians, researchers, patients, and families alike.

Three renowned experts in the field will speak during the event: Dr. Jordan Orange, Dr. Isabelle Meyts, and Dr. Luigi Notarangelo. Together, their perspectives will provide attendees with a comprehensive understanding of the field, as well as new developments in treatment methodologies, and research updates.

“By bringing together different perspectives, the JMF Speaker Series will ensure that the latest PI education reaches the people who need it most. Our goal is to prepare physicians and patients with the knowledge to transform outcomes and improve quality of life,” said Vanessa Tenembaum, CEO of JMF.

What’s Next
Future sessions will feature expert immunologists, JMF research grant recipients, and patient advocates. Additionally, dedicated patient-focused events will share new treatment updates, lived experiences, and resources for the global PI community—continuing JMF’s legacy of education, collaboration, and compassion.


Registration:
Learn more and register today at: info4pi.org

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Columbia University Vagelos College of Physicians and Surgeons and the Jeffrey Modell Foundation.

CONTACT: Rachel Simoneau, 212-819-0200, rsimoneau@jmfworld.org

View original content to download multimedia:https://www.prnewswire.com/news-releases/jeffrey-modell-foundation-launches-global-speaker-series-302591719.html

SOURCE Jeffrey Modell Foundation

Staff

Recent Posts

RPI Consultants Presents Annual Scholarship to Healthcare Technology Professional

BALTIMORE, Feb. 5, 2026 /PRNewswire/ -- RPI Consultants, a leading ERP implementation, optimization, and software firm…

3 hours ago

BioPhorum announces formation of Strategic Advisory Board to accelerate industry collaboration

LONDON, Feb. 5, 2026 /PRNewswire/ -- BioPhorum, the pharmaceutical industry's most trusted collaborative network for…

3 hours ago

BC Platforms partners with OmicsBank to expand access to large-scale real-world and multi-omics data from India and the UAE

Patient catchment now includes 187 million+ patient lives, enables advanced analytics and AI modeling for…

3 hours ago

Electron Microscopy Market to Reach $10.3 billion, Globally, by 2034 at 8.1% CAGR: Allied Market Research

The electron microscopy market is driven by rapid advancements in nanotechnology, increase in demand for…

3 hours ago

BioNxt Secures Innovative Chaperone Technology to Enhance Oral Thin-Film Drug Delivery

VANCOUVER, BC / ACCESS Newswire / February 5, 2026 / BioNxt Solutions Inc. ("BioNxt" or…

3 hours ago

Pentixapharm Announces Peer-Reviewed Phase 2 Data Back Use of PENTIXAFOR as a Superior Non-invasive PET-Diagnostic for Primary Aldosteronism

In the study, [68Ga]Ga-Pentixafor PET/CT was well tolerated and demonstrated high specificity and moderate sensitivity…

6 hours ago